These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 20448470)

  • 61. Bordetella pertussis and pertussis vaccines.
    Guiso N
    Clin Infect Dis; 2009 Nov; 49(10):1565-9. PubMed ID: 19839747
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prevention of pertussis: An unresolved problem.
    Esposito S; Principi N
    Hum Vaccin Immunother; 2018; 14(10):2452-2459. PubMed ID: 29856680
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pertussis in the Era of New Strains of Bordetella pertussis.
    Souder E; Long SS
    Infect Dis Clin North Am; 2015 Dec; 29(4):699-713. PubMed ID: 26337739
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology.
    Sheridan SL; Frith K; Snelling TL; Grimwood K; McIntyre PB; Lambert SB
    Expert Rev Vaccines; 2014 Sep; 13(9):1081-106. PubMed ID: 25093268
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New pertussis vaccination approaches: en route to protect newborns?
    Locht C; Mielcarek N
    FEMS Immunol Med Microbiol; 2012 Nov; 66(2):121-33. PubMed ID: 22574832
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Is there a need for a new generation of vaccines against pertussis?
    Storsaeter J; Wolter J
    Expert Opin Emerg Drugs; 2006 May; 11(2):195-205. PubMed ID: 16634696
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Whither pertussis?
    Snelling TL; Waddington CS
    Expert Rev Anti Infect Ther; 2015 Feb; 13(2):145-8. PubMed ID: 25426699
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
    Winsnes R; Lønnes T; Møgster B; Berdal BP
    Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bordetella pertussis strain variation and evolution postvaccination.
    Kallonen T; He Q
    Expert Rev Vaccines; 2009 Jul; 8(7):863-75. PubMed ID: 19538113
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies.
    Polewicz M; Gracia A; Garlapati S; van Kessel J; Strom S; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
    Vaccine; 2013 Jun; 31(31):3148-55. PubMed ID: 23684829
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Emergence of Bordetella holmesii as a Causative Agent of Whooping Cough, Barcelona, Spain.
    Mir-Cros A; Codina G; Martín-Gómez MT; Fàbrega A; Martínez X; Jané M; Van Esso D; Cornejo T; Rodrigo C; Campins M; Pumarola T; González-López JJ
    Emerg Infect Dis; 2017 Nov; 23(11):1856-1859. PubMed ID: 29052540
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bordetella pertussis from functional genomics to intranasal vaccination.
    Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
    Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bordetella pertussis: why is it still circulating?
    Guiso N
    J Infect; 2014 Jan; 68 Suppl 1():S119-24. PubMed ID: 24103807
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Shortcomings of pertussis vaccines: why we need a third generation vaccine.
    Poolman JT
    Expert Rev Vaccines; 2014 Oct; 13(10):1159-62. PubMed ID: 25089373
    [TBL] [Abstract][Full Text] [Related]  

  • 75. As immunity wanes, whooping cough returns.
    Chin TL
    Health Aff (Millwood); 2014 Dec; 33(12):2095-8. PubMed ID: 25489026
    [No Abstract]   [Full Text] [Related]  

  • 76. Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection.
    Herzog C
    Expert Rev Vaccines; 2015; 14(8):1065-72. PubMed ID: 26098640
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Factors contributing to pertussis resurgence.
    He Q; Mertsola J
    Future Microbiol; 2008 Jun; 3(3):329-39. PubMed ID: 18505398
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Whooping cough is a risk to infants. The disease is circulating among adolescents and adults].
    Nilsson L; Von Segebaden K; Blennow M; Linde A; Uhnoo I
    Lakartidningen; 2013 Sep 11-17; 110(37):1599-602. PubMed ID: 24163932
    [No Abstract]   [Full Text] [Related]  

  • 79. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
    Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
    Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.